Spero Therapeutics SPRO 深 沪
等待开盘 09-16 09:30:00 美东时间
1.13
-0.010
-0.88%
华盛通- 最 高1.151
- 今 开1.14
- 成交量 22.43万股
- 最 低 1.11
- 昨 收 1.14
- 总市值 6580.54万
- 52周最高 3.08
- 市盈率 静 7.78
- 换手率 0.39%
- 52周最低 1.08
- 委 比 51.65%
- 总股本 5823.48万
- 历史最高 23.639
- 量 比 0.60
- 振 幅 3.60%
- 历史最低 0.5052
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
Meta Platforms To $650? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush raised the price target for Meta Platforms Inc (NASDAQ:META) from $595 to $650. Wedbush analyst Ygal A...
09-14 21:01
HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $5 to $6.
09-14 18:42
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>Spero Therapeutics, Inc. granted 102,000 RSUs and 67,600 stock options to new employees under its 2019 Inducement Plan. The stock options vest 25% on September 1, 2027, with the rest vesting monthly over 36 months. RSUs vest in four equal annual installments starting September 1, 2027. Both are subject to continued employment and the terms of the 2019 Inducement Plan. Spero focuses on developing next-generation medicines for immune-mediated di...
09-03 20:05
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Spero Therapeutics, Inc. announced that CEO Esther Rajavelu will present at the H.C. Wainwright 28th Annual Global Healthcare Conference in New York City on September 15, 2026, at 1:30 PM ET. The presentation will be available via webcast and replay for 90 days post-conference. Spero focuses on advancing next-generation medicines for immune-mediated diseases.
09-02 20:01
Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities
Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities
08-29 05:08
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Spero Therapeutics announced several key milestones in Q2 2026, including an exclusive license agreement for SP001, FDA approval of Utebzi for complicated urinary tract infections, a $105 million non-dilutive financing, and the appointment of Debra Zack, M.D., Ph.D., as Chief Medical Officer. The company reported a net loss of $9.6 million for the quarter, with cash and cash equivalents of $50.8 million, extended to mid-2029 with the financing pr...
08-12 20:01
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Spero Therapeutics (Nasdaq: SPRO) announced it will report its second-quarter 2026 financial results on August 12, 2026, after market close. Management will host a conference call and live webcast at 5:00 pm EDT to discuss the results and provide updates. The call can be accessed via phone or webcast links provided. Spero, a clinical-stage biopharmaceutical company, focuses on advancing next-generation medicines in immunology and inflammation.
08-04 20:01
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Dr. Debra Jeske Zack, a seasoned immunologist with over 25 years of experience, has been appointed as Spero Therapeutics' Chief Medical Officer. Her expertise will strengthen the company's clinical leadership as it advances SP001, a Phase 2-ready third-generation anti-CD40L antibody targeting IgG4-related disease and other immune-mediated conditions. Dr. Zack's leadership is expected to accelerate the development of innovative therapies for patie...
07-27 12:00
信达生物早盘涨逾5% 与公司Spero就IBI355达成独家许可协议
信达生物（01801）早盘涨逾5%，截至发稿，股价上涨4.72%，现报94.30港元，成交额4.17亿港元。 7月14日，据信达生物官微消息，公司与Spe...
07-15 09:44
